Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

February 28, 2003

Primary Completion Date

January 31, 2005

Study Completion Date

July 31, 2007

Conditions
Pancreatic Cancer
Interventions
DRUG

arsenic trioxide

Trial Locations (11)

46601

CCOP - Northern Indiana CR Consortium, South Bend

49085

Lakeland Cancer Care Center at Lakeland Hospital - St. Joseph, Saint Joseph

60153

Loyola University Medical Center, Maywood

60426

Ingalls Memorial Hospital, Harvey

60525

LaGrange Memorial Hospital, LaGrange

61602

Oncology/Hematology Associates of Central Illinois, P.C., Peoria

62526

Decatur Memorial Hospital Cancer Care Institute, Decatur

62701

Central Illinois Hematology Oncology Center, Springfield

60637-1470

University of Chicago Cancer Research Center, Chicago

60201-1781

Evanston Northwestern Health Care - Evanston Hospital, Evanston

46885-5099

Fort Wayne Medical Oncology and Hematology, Incorporated, Fort Wayne

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Chicago

OTHER

NCT00053222 - Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine | Biotech Hunter | Biotech Hunter